Inovio Pharmaceuticals, Inc. (the "Company") filed Amendment No.1 to Prospectus Supplement dated January 27, 2026, which modifies and supplements the Company's prospectus supplement dated July 2, 2025 (the "Prospectus"). This amendment is part of the Company's Form S-3 Registration Statement, declared effective by the Securities and Exchange Commission (SEC) on January 31, 2024. The Prospectus, as amended, relates to the offering of 14,285,715 shares of common stock, par value $0.001 per share, of Inovio Pharmaceuticals, Inc., accompanied by Series A and Series B common stock warrants, and an amendment to the terms of the outstanding Series A Warrants.
On January 27, 2026, the Company entered into amendments to the outstanding Series A Warrants (the "Amendments"), extending their expiration date to 5:00 pm New York City time on March 31, 2026. As of the date of this prospectus supplement, each outstanding Series A Warrant expires at 5:00 pm New York City time on March 31, 2026. All other terms of the Series A Warrants remain unchanged.
The information in this Amendment modifies and supersedes, in part, the information contained in the Prospectus. Any modified or superseded information shall not be deemed to constitute part of the Prospectus, except as so modified or superseded by this Amendment. The Company may further amend or supplement the Prospectus by filing additional amendments or supplements as required.
The Company's common stock is traded on the Nasdaq Capital Market under the symbol "INO." On January 26, 2026, the closing sale price of the Company's common stock was $1.51 per share.
The Company is a "smaller reporting company" under applicable SEC rules and is subject to reduced public company reporting requirements. Investors should read and carefully consider the risks described in the "Risk Factors" section in the Prospectus and in the Company's most recent Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q.
The SEC and state securities regulators have not approved or disapproved these securities or determined if the Prospectus, or any of the supplements or amendments relating thereto, is truthful or complete. Any representation to the contrary is a criminal offense.
The date of this Amendment No.1 is January 27, 2026.
